Next Article in Journal
Excessive Gestational Weight Gain: Long-Term Consequences for the Child
Next Article in Special Issue
Cerebrospinal Fluid and Serum d-Serine Levels in Patients with Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Previous Article in Journal
Adverse Childhood Experiences and Methylation of the FKBP5 Gene in Patients with Psychotic Disorders
Previous Article in Special Issue
Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Peripheral Markers of Depression

by
Aleksander Nobis
*,
Daniel Zalewski
and
Napoleon Waszkiewicz
Department of Psychiatry, Medical University of Bialystok, pl. Brodowicza 1, 16-070 Choroszcz, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(12), 3793; https://doi.org/10.3390/jcm9123793
Submission received: 29 September 2020 / Revised: 9 November 2020 / Accepted: 19 November 2020 / Published: 24 November 2020
(This article belongs to the Special Issue Advances in Markers of Psychiatric Disorders)

Abstract

Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high medical and socioeconomic burden. There is a growing interest in the biological underpinnings of depression, which are reflected by altered levels of biological markers. Among others, enhanced inflammation has been reported in MDD, as reflected by increased concentrations of inflammatory markers—C-reactive protein, interleukin-6, tumor necrosis factor-α and soluble interleukin-2 receptor. Oxidative and nitrosative stress also plays a role in the pathophysiology of MDD. Notably, increased levels of lipid peroxidation markers are characteristic of MDD. Dysregulation of the stress axis, along with increased cortisol levels, have also been reported in MDD. Alterations in growth factors, with a significant decrease in brain-derived neurotrophic factor and an increase in fibroblast growth factor-2 and insulin-like growth factor-1 concentrations have also been found in MDD. Finally, kynurenine metabolites, increased glutamate and decreased total cholesterol also hold promise as reliable biomarkers for MDD. Research in the field of MDD biomarkers is hindered by insufficient understanding of MDD etiopathogenesis, substantial heterogeneity of the disorder, common co-morbidities and low specificity of biomarkers. The construction of biomarker panels and their evaluation with use of new technologies may have the potential to overcome the above mentioned obstacles.
Keywords: depression; biomarkers; inflammatory; interleukins; oxidative stress; brain-derived neurotrophic factor (BDNF); panels; melancholic; atypical depression; biomarkers; inflammatory; interleukins; oxidative stress; brain-derived neurotrophic factor (BDNF); panels; melancholic; atypical

Share and Cite

MDPI and ACS Style

Nobis, A.; Zalewski, D.; Waszkiewicz, N. Peripheral Markers of Depression. J. Clin. Med. 2020, 9, 3793. https://doi.org/10.3390/jcm9123793

AMA Style

Nobis A, Zalewski D, Waszkiewicz N. Peripheral Markers of Depression. Journal of Clinical Medicine. 2020; 9(12):3793. https://doi.org/10.3390/jcm9123793

Chicago/Turabian Style

Nobis, Aleksander, Daniel Zalewski, and Napoleon Waszkiewicz. 2020. "Peripheral Markers of Depression" Journal of Clinical Medicine 9, no. 12: 3793. https://doi.org/10.3390/jcm9123793

APA Style

Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020). Peripheral Markers of Depression. Journal of Clinical Medicine, 9(12), 3793. https://doi.org/10.3390/jcm9123793

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop